MA46459A - Méthode de traitement de lésions rénales aiguës - Google Patents
Méthode de traitement de lésions rénales aiguësInfo
- Publication number
- MA46459A MA46459A MA046459A MA46459A MA46459A MA 46459 A MA46459 A MA 46459A MA 046459 A MA046459 A MA 046459A MA 46459 A MA46459 A MA 46459A MA 46459 A MA46459 A MA 46459A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- acute kidney
- kidney damage
- acute
- damage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
La présente invention concerne des procédés de traitement d'un patient humain souffrant d'une lésion rénale aiguë.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404390P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055400 WO2018067857A1 (fr) | 2016-10-05 | 2017-10-05 | Méthode de traitement de lésions rénales aiguës |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46459A true MA46459A (fr) | 2019-08-14 |
| MA46459B1 MA46459B1 (fr) | 2021-03-31 |
Family
ID=60153507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46459A MA46459B1 (fr) | 2016-10-05 | 2017-10-05 | Méthode de traitement de lésions rénales aiguës |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20210283116A1 (fr) |
| EP (1) | EP3522880B1 (fr) |
| JP (1) | JP7065839B2 (fr) |
| KR (1) | KR20190062502A (fr) |
| CN (1) | CN109789117B (fr) |
| AU (1) | AU2017340760B2 (fr) |
| BR (1) | BR112019005539A2 (fr) |
| CA (1) | CA3036723A1 (fr) |
| CO (1) | CO2019004561A2 (fr) |
| CY (1) | CY1124759T1 (fr) |
| DK (1) | DK3522880T3 (fr) |
| ES (1) | ES2859487T3 (fr) |
| HR (1) | HRP20210294T1 (fr) |
| HU (1) | HUE053557T2 (fr) |
| IL (1) | IL265749A (fr) |
| JO (1) | JOP20190056B1 (fr) |
| LT (1) | LT3522880T (fr) |
| MA (1) | MA46459B1 (fr) |
| MD (1) | MD3522880T2 (fr) |
| MX (1) | MX387518B (fr) |
| MY (1) | MY192385A (fr) |
| PH (1) | PH12019500725A1 (fr) |
| PL (1) | PL3522880T3 (fr) |
| PT (1) | PT3522880T (fr) |
| RS (1) | RS61573B1 (fr) |
| RU (1) | RU2753607C2 (fr) |
| SG (1) | SG11201901925RA (fr) |
| SI (1) | SI3522880T1 (fr) |
| SM (1) | SMT202100111T1 (fr) |
| TW (1) | TWI778982B (fr) |
| UA (1) | UA124019C2 (fr) |
| WO (1) | WO2018067857A1 (fr) |
| ZA (1) | ZA201901743B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016333963C1 (en) | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| US11358954B2 (en) * | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN109843857B (zh) * | 2016-10-05 | 2023-01-06 | 米托布里奇公司 | Ppar激动剂化合物的结晶和盐形式 |
| WO2021013772A1 (fr) | 2019-07-19 | 2021-01-28 | Vifor (International) Ag | Inhibiteurs de ferroportine destinés à être utilisés dans la prévention et le traitement de lésions rénales |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CA3212825A1 (fr) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Composes utiles pour le traitement des maladies du foie |
| WO2022189856A1 (fr) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Composés utiles pour le traitement des maladies du foie |
| CN115813901B (zh) * | 2022-10-20 | 2024-10-22 | 南京市儿童医院 | 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2539403C (fr) | 2003-09-19 | 2013-11-19 | Janssen Pharmaceutica N.V. | Acides 4-((phenoxyalkyl)thio)-phenoxyacetiques et analogues |
| RU2006145872A (ru) * | 2004-05-25 | 2008-06-27 | Метаболекс, Инк. (Us) | Замещенные триазолы в качестве модуляторов ppar и способы их получения |
| RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
| JP2016512201A (ja) | 2013-03-08 | 2016-04-25 | アッヴィ・インコーポレイテッド | 急性腎障害の治療方法 |
| JP2016520552A (ja) * | 2013-04-05 | 2016-07-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Ｐｐａｒアゴニスト |
| EP2862574A1 (fr) | 2013-10-15 | 2015-04-22 | Sanofi | Acide {4-[5-(3-chloro-phénoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-diméthyl-phénoxy}-acétique pour son utilisation dans la prévention ou le traitement de l'insuffisance rénale aiguë |
| CN110007084B (zh) * | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| WO2016057656A1 (fr) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Agonistes ppar-delta destinés à être utilisés pour le traitement d'affections mitochondriales, vasculaires, musculaires et démyélynisantes |
| AU2016333963C1 (en) * | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
-
2017
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
- 2017-10-05 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en not_active Ceased
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/fr active Active
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 MX MX2019003949A patent/MX387518B/es unknown
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 CA CA3036723A patent/CA3036723A1/fr active Pending
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Ceased
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh not_active IP Right Cessation
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/fr not_active Ceased
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
- 2017-10-05 SM SM20210111T patent/SMT202100111T1/it unknown
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 BR BR112019005539-8A patent/BR112019005539A2/pt not_active Application Discontinuation
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46459B1 (fr) | Méthode de traitement de lésions rénales aiguës | |
| EP3813647A4 (fr) | Stimulation multimodale de traitement des tremblements | |
| EP3644996A4 (fr) | Procédés de traitement de la maladie de huntington | |
| MA49760B1 (fr) | Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| MA47408B1 (fr) | Traitement du cancer | |
| EA201790413A1 (ru) | Антитела против tigit | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| EP3362013C0 (fr) | Dispositif energetique pour le traitement d'un trouble oculaire | |
| MX2016010173A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| EP3686818A4 (fr) | Système de traitement de l'eau | |
| MA52024A (fr) | Système de traitement de l'eau | |
| EA201791101A1 (ru) | Способы лечения рассеянного склероза | |
| EA201692472A1 (ru) | Соединения для лечения рака мозга | |
| EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| MX2018004132A (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
| EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
| MA40607B1 (fr) | Traitements médicaux à base d'anamoréline | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| EP4085053A4 (fr) | Traitement du cancer avec des inhibiteurs de cdk12/13 | |
| EP3775171A4 (fr) | Procédés de traitement d'un cancer résiduel minimal | |
| EP3829713C0 (fr) | Système de traitement de tissu adipeux | |
| EA201890347A1 (ru) | Антитела и исследования для обнаружения cd37 |